Pfizer on Tuesday reported second-quarter outcomes that topped estimates and hiked the low finish of its income outlook, citing an anticipated $1.5 billion bump in gross sales from its non-Covid merchandise.
The corporate is now anticipating full-year income to whole $60.5 billion to $62.5 billion, which compares with a earlier outlook of $59.5 billion to $62.5 billion. That gross sales vary would nonetheless be roughly flat or down barely in contrast with 2025 income of $62.6 billion.
Pfizer stated it minimize its full-year income expectation for its Covid merchandise – the vaccine Comirnaty and antiviral tablet Paxlovid – to $4 billion, down from round $5 billion beforehand.
“Low COVID-19 incidence might proceed to restrict Paxlovid utilization,” Pfizer’s incoming interim CFO, Cecile Guegan, stated through the firm’s second-quarter earnings name. “Our plan additionally assumes nearly all of Comirnaty gross sales will happen towards year-end, according to the vaccination season.”
The pharmaceutical large reiterated its full-year adjusted revenue outlook of between $2.80 and $3 per share.
Pfizer additionally introduced extra financial savings of $2.5 billion from two separate cost-cutting applications, which might be achieved beginning in 2027 and thru 2029.
“With our robust efficiency by means of the primary half of the 12 months and our ongoing productiveness enhancement self-discipline, we stay assured in our enterprise,” Pfizer CEO Albert Bourla stated on the decision.
Here is what the corporate reported for the second quarter in contrast with what Wall Avenue was anticipating, based mostly on a survey of analysts by LSEG:
- Earnings per share: 77 cents adjusted vs. 68 cents anticipated
- Income: $15.03 billion vs. $14.41 billion anticipated
Pfizer reported income of $15.03 billion for the primary quarter, up 3% from the identical interval a 12 months in the past. Gross sales will increase for key merchandise, together with its blood thinner Eliquis and focused most cancers drug Padcev, helped to counteract struggles in its Covid enterprise.
Eliquis specifically blew previous estimates for the quarter, raking in $2.43 billion in gross sales, up 19%. Analysts had been anticipating income of $2.08 billion, based on StreetAccount.
Lately launched and bought merchandise additionally delivered $3.2 billion in income through the quarter, Guegan stated through the name.
“Our business efficiency has additionally helped mitigate the influence of at present low Covid an infection ranges,” she stated.
The corporate booked a internet lack of $248 million, or 4 cents per share, for the interval. That compares with internet earnings of $2.91 billion, or 51 cents per share, through the second quarter of 2025.
The quarterly loss largely mirrored a $4.3 billion noncash impairment cost after Pfizer lowered its income expectations for sure merchandise, primarily following disappointing late-stage trial outcomes for its drug sigvotatug vedotin in beforehand handled non-small-cell lung most cancers.
The cost additionally mirrored the elimination of income projections for its sickle cell illness drug Oxbryta after current discussions with the Meals and Drug Administration. Pfizer pulled that product from the market in 2024.
Excluding sure gadgets, together with restructuring costs and prices related to intangible belongings, Pfizer posted earnings per share of 77 cents for the quarter.
The corporate additionally introduced the second section of a multiyear initiative to slash prices, which targets round $1.5 billion in financial savings by means of 2029. That section focuses on what the corporate referred to as product portfolio enhancements, community construction adjustments and extra operational efficiencies.
The primary a part of that effort is on monitor to ship $1.5 billion in financial savings by the tip of 2027.
Pfizer introduced a further $1 billion in financial savings from a separate cost-cutting program, which might be achieved from 2027 to 2029. That provides to the beforehand introduced $5.7 billion in value financial savings the corporate will obtain by means of this system by the tip of the 12 months.
The pharmaceutical large is seeking to longer-term investments in its pipeline, together with its current $10 billion acquisition of the weight problems biotech Metsera, to counter waning Covid product gross sales and declines from older medication. Buyers are centered on a number of essential knowledge releases from Pfizer this 12 months, together with knowledge on a mixture routine that features its GLP-1 injection and an amylin asset.
